The ClinicianThe ClinicianКлиницист1818-83382412-8775Publishing House ABV Press7210.17650/1818-8338-2012-1-63-67ORIGINAL INVESTIGATIONSОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕCLINICAL AND INSTRUMENTAL DATA AND SURVIVAL IN DILATED CARDIOMYOPATHY: THREE-YEAR OBSERVATION RESULTSКЛИНИКО-ИНСТРУМЕНТАЛЬНЫЕ ПОКАЗАТЕЛИ И ВЫЖИВАЕМОСТЬ ПРИ ДИЛАТАЦИОННОЙ КАРДИОМИОПАТИИ: РЕЗУЛЬТАТЫ ТРЕХЛЕТНЕГО НАБЛЮДЕНИЯZotovaL. A.ЗотоваЛ. А.
Russian Federation

Department of Hospital Therapy

Кафедра госпитальной терапии

dr.zotova@gmail.comRyazan State Ivan Petrovich Pavlov Medical UniversityГБОУ ВПО РязГМУ им. акад. И.П. Павлова Минздравсоцразвития России150120126163671607201416072014Copyright ©; 2012, Zotova L.A.Copyright ©; 2012, Зотова Л.А.2012Zotova L.A.Зотова Л.А.https://creativecommons.org/licenses/by/4.0https://klinitsist.abvpress.ru/Klin/article/view/72

Aim — to assess survival of patients with dilated cardiomyopathy (DCM) in 3‑year follow-up based on clinical history, clinical symptoms, indicators of instrumental methods of examination and tactics of the patients.

Materials and methods. 105 patients with diagnosed cardiomyopathy were included in prospective single-center study. Follow‑up period was 3 years or until achieving primary endpoint. Complaints were collected, general clinical research, 6-minute walk test, electrocardiography in 12‑lead were performed annually. Also scale of evaluation of clinical status in patients with chronic heart failure (CHF) in the modification of V.Y. Mareev and assessment of adherence were used annualy.

Results. The group of patients with DCM was represented primarily by man, severe heart failure (III–IV functional class) was originally diagnosed in almost 80 % of patients. During the 3 years of follow-up progression of heart failure, worsening of hemodynamic indices were identified in survivors. When evaluating recommended therapy with found that it meets the current guidelines of treatment of heart failure,however, low adherence to treatment of patients was revealed with statistically significant difference between groups of survivors and deceased patients. The annual mortality rate was 20 % and had no significant fluctuations. The main cause of death was heart failure decompensation.

Conclusion. Progression of CHF in patients with DCM was confirmed .The most reliable method of assessing the progressive course of heart failure is 6‑minute walk test. The annual high mortality (20 %) indicates an extremely poor prognosis for this disease. The major causes of death were progression of heart failure and sudden cardiac death.

dilated cardiomyopathychronic heart failurediagnosissurvivalдилатационная кардиомиопатияхроническая сердечная недостаточностьдиагностикавыживаемость1. Агеев Ф.Т., Даниелян М.О., Мареев В.Ю. и др. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА‑О‑ХСН). Журнал Сердечная недостаточность 2003;4(5):4−8.Агеев Ф.Т., Даниелян М.О., Мареев В.Ю. и др. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА‑О‑ХСН). Журнал Сердечная недостаточность 2003;4(5):4−8.2. Национальные рекомендации ВНОК И ОССН по диагностикеи лечению ХСН (третий пересмотр).Национальные рекомендации ВНОК И ОССН по диагностикеи лечению ХСН (третий пересмотр).Журнал Сердечная недостаточность 2010;11(1):1−57.3. Cowie M.R., Wood D.A., Coats A.J., et al. Survival of patient with a new diagnosis of heart failure: a population based study. Heart 2000;83:505−10.Cowie M.R., Wood D.A., Coats A.J., et al. Survival of patient with a new diagnosis of heart failure: a population based study. Heart 2000;83:505−10.4. Шумаков В.И., Хубутия М.Ш., Ильинский И.М. Дилатационная кардиомиопатия. Тверь: Триада, 2003.Шумаков В.И., Хубутия М.Ш., Ильинский И.М. Дилатационная кардиомиопатия. Тверь: Триада, 2003.5. Амосова Е.Н. Кардиомиопатии. К.: Книга плюс, 1999.Амосова Е.Н. Кардиомиопатии. К.: Книга плюс, 1999.6. Luk A., Ahn E., Soor G.S., Butany J. Dilated cardiomyopathy: a review. J Clin Pathol 2009;62:219−25.Luk A., Ahn E., Soor G.S., Butany J. Dilated cardiomyopathy: a review. J Clin Pathol 2009;62:219−25.7. Burkett E.L., Hershberger R.E. Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 2005; 45(7):969−81.Burkett E.L., Hershberger R.E. Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 2005; 45(7):969−81.8. Jefferies J., Towbin J. Dilated cardiomyopathy. Lancet 2010;375:752−62.Jefferies J., Towbin J. Dilated cardiomyopathy. Lancet 2010;375:752−62.9. Maron B.J., Towbin J.A., Thiene G., et al.; American Heart Association; Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; Council on EpidemiologyMaron B.J., Towbin J.A., Thiene G., et al.; American Heart Association; Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; Council on Epidemiologyand Prevention. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006;113:1807−16.10. Беленков Ю.Н., Мареев В.Ю. Методы оценки тяжести ХСН и оценки результатов лечения. М., 2002.Беленков Ю.Н., Мареев В.Ю. Методы оценки тяжести ХСН и оценки результатов лечения. М., 2002.11. Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of selfreported measure of medical adherence. Med Care 1986;24:67−73.Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of selfreported measure of medical adherence. Med Care 1986;24:67−73.12. Надлежащая клиническая практика: [ГОСТ Р 52379-2005]. М.: Стандартинформ, 2006.Надлежащая клиническая практика: [ГОСТ Р 52379-2005]. М.: Стандартинформ, 2006.13. Declaration of Helsinki. World Medical Association. Available from: http://www.wma.net/e/ethicsunit/helsinki.htmDeclaration of Helsinki. World Medical Association. Available from: http://www.wma.net/e/ethicsunit/helsinki.htm14. Гланц C. Медико-биологическая статистика. 4‑е изд. М.: Практика, 1999.Гланц C. Медико-биологическая статистика. 4‑е изд. М.: Практика, 1999.15. Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М.: МедиаСфера, 2002.Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М.: МедиаСфера, 2002.